Clinical trial
Efficacy and Safety of Tenecteplase Thrombolysis as Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours: A Multicenter Randomized Controlled Clinical Trial
NCT07912970 is registered in ClinicalTrials.gov with Fujian Medical University Union Hospital as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started April 2027. Interventional study, Phase 3, 1,266 participants (estimated). Lead sponsor Fujian Medical University Union Hospital; China. Primary measure: Functional Independence at 90 Days.
How it compares
263 similar trials: same condition (Ischemic Stroke) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Tenecteplase Thrombolysis as Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours: A Multicenter Randomized Controlled Clinical Trial
- Lead sponsor
- Fujian Medical University Union Hospital
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- April 1, 2027
- Completion date
- March 1, 2030
- Enrollment
- 1,266 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: acute ischemic stroke, large vessel occlusion
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 1
- Countries
- China
- Lead sponsor
- Fujian Medical University Union Hospital
Arms
As registered; 2 arms.
| Arm | Type | Interventions |
|---|---|---|
| Tenecteplase Group | Experimental | Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg) |
Show registry wordingParticipants will receive intravenous tenecteplase at a dose of 0.25 mg/kg, with a maximum dose of 25 mg, as a single bolus before interhospital transfer. Interhospital transfer to a thrombectomy-capable stroke center will be initiated immediately after tenecteplase administration. At the receiving center, participants will be evaluated for endovascular therapy and treated according to current clinical guidelines. | ||
| Direct-Transfer Group | No intervention | |
Show registry wordingParticipants are transferred directly to the receiving stroke center without study-assigned intravenous tenecteplase before transfer. At the receiving center, they are evaluated for endovascular therapy, which is performed if clinically indicated. Participants receive standard medical care according to clinical needs. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Functional Independence at 90 Days | Day 90 ± 7 days after randomization |
Show registry wordingProportion of participants with functional independence at 90 days after randomization, defined as a modified Rankin Scale score of 0 to 2. The modified Rankin Scale ranges from 0 to 6, with lower scores indicating less disability. | |
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
Tenecteplase
- US 5385732; expires June 2, 2014; assignee Genentech
Lead sponsor's other trials
Fujian Medical University Union Hospital, most recent start first.
+103 more trials
Similar trials
Same condition (Ischemic Stroke) and phase, most recent start first.
+258 more trials See the condition page